The State University of New York

NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous system (CNS) disorders, today announced seven presentations from across its broad portfolio of innovative neuroscience products and product candidates at Psych Congress 2024, being held Oct. 29 - Nov. 2, 2024, in Boston, Massachusetts. Details for the presentations are as follows: Major Depressive Disorder Title: AXS-05 (Auvelity®) in Major Depressive Disorder: Pooled Data from Two Six-Week Controlled Trials (GEMINI and ASCEND)Presentation Date and Time: Thursday, Oct. 31, 1:30 - 3 p.m. and Friday, Nov. 1, 1:30 - 3 p.m. ETLead Author: Craig Chepke, MD, SUNY Upstate Medical UniversityPoster Number: 171 Title: Effects of AXS-05 (Auvelity®) in Improving Anhedonia and Interest-Activity Symptoms of MDD and the Associated Improvements in Functional Impairment Presentation Date and Time: Thursday, Oct. 31, 1:30 - 3 p.m. and Friday, Nov. 1, 1:30 - 3 p.m. ETLead Author: Roger McIntyre, MD, Professor of Psychiatry and Pharmacology at the University of TorontoPoster Number: 172 Title: Real-World Treatment Experiences and Expectations by Symptom Severity in Patients with Major Depressive DisorderPresentation Date and Time: Thursday, Oct. 31, 1:30 - 3 p.m. and Friday, Nov. 1, 1:30 - 3 p.m. ETLead Author: Roger McIntyre, MD, Professor of Psychiatry and Pharmacology at the University of TorontoPoster Number: 198 Alzheimer’s Disease Agitation Title: Clinical Profile of AXS-05 in Treating Alzheimer’s Disease-Related Agitation: Results from The Phase 2/3 Development ProgramPresentation Date and Time: Thursday, Oct. 31, 1:30 - 3 p.m. and Friday, Nov. 1, 1:30 - 3 p.m. ETLead Author: Jeffrey Cummings, MD, ScD, Vice Chair of Research, UNLV Department of Brain HealthPoster Number: 45 OSA and Narcolepsy Title: Solriamfetol for Excessive Daytime Sleepiness in Patients with Narcolepsy and OSA Reporting Anxiety and Depression in the Real-World SURWEY StudyPresentation Date and Time: Thursday, Oct. 31, 1:30 - 3 p.m. and Friday, Nov. 1, 1:30 - 3 p.m. ETLead Author: Ulf Kallweit, MD, Assistant Professor of Neurology at the University Witten/Herdecke, GermanyPoster Number: 20 Cognition Title: Effects of Solriamfetol on Cognition in Obstructive Sleep Apnea with Excessive Daytime Sleepiness and Impaired Cognition in the SHARP Clinical TrialPresentation Date and Time: Thursday, Oct. 31, 1:30 - 3 p.m. and Friday, Nov. 1, 1:30 - 3 p.m. ETLead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, GermanyPoster Number: 92 Title: Effects of Solriamfetol on Cognition in Patients with Excessive Daytime Sleepiness Associated with Narcolepsy in the Real-World SURWEY StudyPresentation Date and Time: Thursday, Oct. 31, 1:30 - 3 p.m. and Friday, Nov. 1, 1:30 - 3 p.m. ETLead Author: Yaroslav Winter, MD, Mainz Comprehensive Epilepsy and Sleep Medicine Center, department of neurology, Johannes Gutenberg-University, Mainz, GermanyPoster Number: 164 About Axsome Therapeutics Axsome Therapeutics, Inc. is a biopharmaceutical company developing and delivering novel therapies for central nervous system (CNS) conditions that have limited treatment options. Through development of therapeutic options with novel mechanisms of action, we are transforming the approach to treating CNS conditions. At Axsome, we are committed to developing products that meaningfully improve the lives of patients and provide new therapeutic options for physicians. For more information, please visit the Company’s website at www.axsome.com. Forward Looking Statements Certain matters discussed in this press release are “forward-looking statements”. The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. In particular, the Company’s statements regarding trends and potential future results are examples of such forward-looking statements. The forward-looking statements include risks and uncertainties, including, but not limited to, the continued commercial success of the Company’s Sunosi® and Auvelity® products and the success of the Company’s efforts to obtain any additional indication(s) with respect to solriamfetol and/or AXS-05; the Company’s ability to maintain and expand payer coverage; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund the Company’s disclosed clinical trials, which assumes no material changes to the Company’s currently projected revenues or expenses), futility analyses and receipt of interim results, which are not necessarily indicative of the final results of the Company’s ongoing clinical trials, and/or data readouts, and the number or type of studies or nature of results necessary to support the filing of a new drug application (“NDA”) for any of the Company’s current product candidates; the Company’s ability to fund additional clinical trials to continue the advancement of the Company’s product candidates; the timing of and the Company’s ability to obtain and maintain U.S. Food and Drug Administration (“FDA”) or other regulatory authority approval of, or other action with respect to, the Company’s product candidates, including statements regarding the timing of any NDA submission; whether issues identified by FDA in the complete response letter may impact the potential approvability of the Company’s NDA for AXS-07 for the acute treatment of migraine in adults with or without aura, pursuant to the Company’s special protocol assessment for the MOMENTUM clinical trial; the Company’s ability to successfully defend its intellectual property or obtain the necessary licenses at a cost acceptable to the Company, if at all; the successful implementation of the Company’s research and development programs and collaborations; the success of the Company’s license agreements; the acceptance by the market of the Company’s products and product candidates, if approved; the Company’s anticipated capital requirements, including the amount of capital required for the continued commercialization of Sunosi and Auvelity and for the Company’s commercial launch of its other product candidates, if approved, and the potential impact on the Company’s anticipated cash runway; the Company’s ability to convert sales to recognized revenue and maintain a favorable gross to net sales; unforeseen circumstances or other disruptions to normal business operations arising from or related to domestic political climate, geo-political conflicts or a global pandemic and other factors, including general economic conditions and regulatory developments, not within the Company’s control. The factors discussed herein could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release and the Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstance. Investors:Mark JacobsonChief Operating Officer(212) 332-3243mjacobson@axsome.com Media:Darren OplandDirector, Corporate Communications(929) 837-1065dopland@axsome.com

COLTS NECK, N.J., Oct. 28, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Peter M. Farrugia is acknowledged as a 2024 Pinnacle Lifetime Member for his contributions to the field of Interventional Cardiology. Dr. Farrugia pursued higher education at Kings College where he earned a Bachelor of Science degree in Biology and Molecular Biology with Summa Cum Laude honors. He then obtained his MD at the Renaissance School of Medicine at Stony Brook University. He completed his Internal Medicine Program at SUNY Stony Brook, followed by a cardiovascular disease fellowship at St. Vincent's Catholic Medical Center in Manhattan. He further specialized in interventional cardiology through training at Winthrop University Hospital. The doctor holds certifications in cardiovascular disease and interventional cardiology, as well as being a Registered Physician in Vascular Interpretation (RPVI). A dedicated interventional cardiologist and vascular specialist, Dr. Farrugia notes that he has been instrumental in providing high-quality cardiac and vascular care to patients in Monmouth and Ocean County. He currently serves as the CEO of Advanced Heart and Vascular of Central Jersey which he explained is a practice that prioritizes the physician-patient relationship and focuses on delivering exceptional care. The doctor explained that interventional cardiology involves catheter-based treatments for structural heart diseases, while vascular surgery addresses vascular issues through medical therapy, minimally-invasive procedures, and surgical reconstruction. With more than 10 years in the field, Dr. Farrugia is an expert in interventional cardiology and vascular care, and is well-known in the field for advanced techniques and procedures aimed at diagnosing and treating structural heart diseases and vascular conditions. A leader in the field, the doctor is affiliated with many professional organizations, including the American College of Cardiology (FACC). During his tenure as an interventional cardiologist, Dr. Farrugia has held key roles in various medical institutions, including serving as the Director of Outpatient Vascular Medicine and Chief of the Cardiac Catheterization Lab at Monmouth Medical Center. Dr. Farrugia is credited with improving care delivery models, and has received recognition as a Fellow of the American College of Cardiology (FACC). Aside from his professional pursuits, Dr. Farrugia is a sports coach, and trains in ballroom dancing with his family of which he also enjoys spending his spare time. Contributing positively to his community, the doctor acknowledges the unwavering support of his wife, Erin, and their four children. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

The ABTA has invested more than $36 million in over 800 research projects, leading the charge in advancing progress and fostering hope for life-changing treatments and care for brain tumor patients. CHICAGO, Oct. 22, 2024 /PRNewswire/ -- The American Brain Tumor Association (ABTA) is proud to announce its ongoing commitment to brain tumor research with the funding of 24 new research projects. For more than 50 years, the ABTA has remained committed to funding brain tumor research, especially for early-stage investigators. This investment, which starts with the earliest phase of medical training, seeks to not only drive brain tumor research forward, but empower the next generation of physicians and scientists to propel the neuro-oncology field forward. "Through the funding of brain tumor research, the ABTA empowers talented researchers to pursue challenging questions in neuro-oncology," says Ralph DeVitto, ABTA president and chief executive officer. "We are proud to continue our legacy of funding critical brain tumor research and bringing hope to patients." This year's slate of awarded grants includes research projects that span several areas of brain tumor research, including biomarkers, epigenetics, experimental therapeutics, immunotherapy, and invasion for adult and pediatric brain tumors. The ABTA extends its congratulations to the 2024 grant recipients listed below. To learn more about current ABTA grant recipients, visit abta.org/research/research-funding-impact-2. Research Collaboration Grants are two-year, $200,000 grants awarded for multi-investigator multidisciplinary brain tumor collaborative research projects. Grant awardees include: Jacques Lux, PhD–University of Texas Southwestern Medical Center, with Co-PI Wen Jiang, MD, PhD–University of Texas M.D. Anderson Cancer Center Pavithra Viswanath, PhD–University of California, San Francisco, with Co-PI, Peng Zhang, PhD–Northwestern University Basic Research Fellowships are two-year, $100,000 mentored grants awarded to post-doctoral fellows to retain talented researchers in the neuro-oncology field. Fellowship awardees include: Adam Grippin, MD, PhD–University of Texas M.D. Anderson Cancer Center Mark Youngblood, MD, PhD–Northwestern University Discovery Grants are one-year, $50,000 grants supporting innovative, bold, high-impact approaches with the potential to transform current diagnostic or treatment standards of care. Grant awardees include: Toshiro Hara, PhD–University of Michigan Tanner Johanns, MD, PhD–Washington University in St. Louis Julie Miller, MD, PhD–Massachusetts General Hospital Chrystian Junqueira Alves, PhD–Icahn School of Medicine at Mount Sinai Gilbert Rahme, PhD–State University of New York at Stony Brook David Raleigh, MD, PhD–University of California, San Francisco Artak Tovmasyan, PhD–Dignity Health/St. Joseph's Hospital & Medical Center Dionysios Watson, MD, PhD–Sylvester Comprehensive Cancer Center/University of Miami Peng Zhang, PhD–Northwestern University Medical Student Summer Fellowships are three-month, $3,000 grants awarded to medical students to conduct brain tumor research projects under the mentorship of neuro-oncology experts. Fellows include: Lucy Chen, AB–Johns Hopkins University School of Medicine Harrsha Congivaram, BS–Northwestern University Feinberg School of Medicine Karenna Groff, MEng–New York University Grossman School of Medicine Joseph Inger, BS–Brown University Jill Jones, BS–Boston Children's Hospital Seth Meade, BSE–Cleveland Clinic Jonathon Mitchell, BS–Miller School of Medicine of the University of Miami Megan Parker, BS–Johns Hopkins University School of Medicine Jorge Salcedo, AB, AB–University of California, Los Angeles Ethan Schonfeld, MS–Stanford University Suchet Taori, BA–University of Pittsburgh Awarding of these grants would not be possible without the incredible support of our donors and our partner organizations including the Joel A. Gingras Memorial Foundation, Southeastern Brain Tumor Foundation, BrainUp, Tap Cancer Out, and Gladiator Project. The ABTA will soon begin accepting applications for its 2025 Discovery Grants, Basic Research Fellowships, and Jack and Fay Netchin Medical Student Summer Fellowships. In addition, ABTA partnered grants, the CNS Metastasis Research Grant and Brain Tumor Funders' Collaborative grant, will begin accepting applications soon. For more information on grant opportunities and deadlines, visit abta.org/grants. About the ABTA Founded in 1973, the American Brain Tumor Association provides comprehensive resources to support the complex needs of brain tumor patients and caregivers, across all ages and tumor types, as well as the critical funding of research in the pursuit of breakthroughs in brain tumor diagnoses, treatments, and care. To learn more, visit abta.org or call 800-886-ABTA (2282). SOURCE American Brain Tumor Association WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED